- {{heading}}
- Ab02806-23.0 Anti-HIV-1 GP120 [VRC03]
- HIV-1
- Rabbit IgG
- Purified
- Ships in 4-5 weeks
- Ab02806-10.0 Anti-HIV-1 GP120 [VRC03]
- HIV-1
- Human IgG1
- Purified
- In Stock
Recombinant monoclonal antibody to HIV-1 GP120. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the human B cell clone VRC03.
UniProt Accession Number of Target Protein: P35961
Alternative Name(s) of Target: Glycoprotein 120; SU; surface protein gp120; env polyprotein; envelope glycoprotein gp16
Immunogen: The original antibody was generated from human B cells obtained from an HIV infected donor.
Specificity: This antibody binds CD4 binding site of the HIV-1 GP120.
Application Notes: The binding profile of this antibody towards HIV-1 GP120 was studied using ELISA and surface plasmon resonance. The original VRC03 IgG1 antibody, successfully neutralizes over 50% of current circulating HIV-1 isolates. (Mascola et al., US8637036). This antibody was reported to bind the resurfaced stabilized core 3 (RSC3) of the mutated HIV-1 envelop glycoprotein that is also capable of binding CD4. The original IgG1 version of this antibody has a binding affinity of KD = 7.31 × 10–8 M. (PMID: 20616233). VRC03 was found to potently inhibit entry into CD4+ T cells of HIV isolated from the latent viral reservoir of infected individuals whose plasma viremia was well controlled by antiretroviral therapy (ART) (PMID: 25157148).
Antibody first published in:
Wu et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science. 2010 Aug 13; 329(5993): 856–861. PMID:20616233
Note on publication:
Describes the generation and isolation of CD4-binding site specific neutralizing antibodies from the sera of an HIV-1–infected donor.